Related Experiment Videos
Validity and reliability of the Korean version of the pediatric quality of life ESRD module
Ki-Soo Park1, Min Hyun Cho, Il Soo Ha
1Department of Preventive Medicine and Institute of Health Sciences, Gyeongsang National University Hospital, 816-15 Jinjudae-ro, Jinju 660-751, South Korea.
Insights
This study validated the Korean version of a quality of life tool for children with end-stage renal disease. The PedsQL 3.0 End-Stage Renal Disease Module is a feasible and valid measure for assessing health-related quality of life in these pediatric patients.
Area of Science:
- Pediatric Nephrology
- Health Outcomes Research
- Quality of Life Assessment
Background:
- Health-related quality of life (HRQoL) is crucial for children with end-stage renal disease (ESRD) and their families, often presenting lifelong challenges.
- Pediatric ESRD requires long-term management, including dialysis and renal transplantation, significantly impacting patients' well-being.
Purpose of the Study:
- To validate the Korean version of the PedsQL 3.0 End-Stage Renal Disease Module for assessing HRQoL in Korean pediatric patients.
- To evaluate the feasibility and psychometric properties of a disease-specific HRQoL instrument for children with ESRD.
Main Methods:
- A cross-sectional study involving 92 pediatric patients (aged 2-18 years) with ESRD undergoing renal replacement therapy across four Korean teaching hospitals.
- Validation of the Korean PedsQL 3.0 ESRD Module against the PedsQL 4.0 Generic Core Scales using parent proxy-reports and child self-reports.
- Assessment of response rates, missing values, face validity, feasibility, floor/ceiling effects, and construct validity.
Main Results:
- The Korean PedsQL 3.0 ESRD Module demonstrated acceptable feasibility, with minimal missing values and good face validity.
- Validation analyses indicated acceptable floor and ceiling effects and satisfactory construct validity when compared to the generic PedsQL 4.0.
- The module was well-accepted by both parents and children for reporting HRQoL.
Conclusions:
- The PedsQL 3.0 End-Stage Renal Disease Module is a potentially valuable, disease-specific tool for evaluating HRQoL in Korean children with ESRD.
- Further research with larger, longitudinal studies is recommended to confirm the long-term utility of this instrument.
Background:
Health-related quality of life is a very important issue in children with end-stage renal disease and their family. Moreover, this can be a lifelong problem. In this study, we performed a cross-sectional investigation of the health-related quality of life in Korean children, undergoing renal replacement therapies, such as dialysis and renal transplantation.
Findings:
We validated the Korean version of the PedsQL 3.0 End-Stage Renal Disease Module by comparing with the PedsQL 4.0 Generic Core Scales. A total of 92 pediatric patients with end-stage renal disease, aged 2-18 year old, were enrolled in four teaching hospitals in Korea. The module was acceptable for both parent proxy-report and child self-report. The response rate was acceptable, since no reminders were delivered. A large proportion of the responders answered > 90% of the items, which suggests a good face validity. The PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 End-Stage Renal Disease Module showed minimal missing values in the current study, which supported feasibility. The validation analyses revealed acceptable floor and ceiling effects and an acceptable construct validity.
Conclusions:
The PedsQL 3.0 End-stage Renal Disease Module may be useful as an end-stage renal disease -specific instrument in the evaluation of the health-related quality of life in Korean children; however, a larger, longitudinal prospective study is needed.
Related Concept Videos
Reliability and Validity
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Kidney Transplant I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant II: Surgical Procedure
Pharmacokinetics in Pediatric Patients: Drug Excretion